Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying CYP2D6*4 Variants: A Case Report

We report two cases of patients who developed severe adverse drug reactions including persistent movement disorders, nausea, and vertigo during treatment with quetiapine at maximum daily doses ranging between 300 and 400 mg. The extensive hepatic metabolism of quetiapine is mainly attributed to cytochrome P450 3A4 (CYP3A4). However, there is recent evidence supporting the idea of CYP2D6 playing a role in the clearance of the quetiapine active metabolite norquetiapine. Interestingly, both patients we are reporting of are carriers of the CYP2D6*4 variant, predicting an intermediate metabolizer phenotype. Additionally, co-medication with a known CYP2D6 inhibitor and renal impairment might have further affected quetiapine pharmacokinetics. The herein reported cases could spark a discussion on the potential impact of a patient’s pharmacogenetic predisposition in the treatment with quetiapine. However, further studies are warranted to promote the adoption of pharmacogenetic testing for the prevention of drug-induced toxicities associated with quetiapine.

[1]  H. E. Meyer zu Schwabedissen,et al.  Enriching Medication Review with a Pharmacogenetic Profile – A Case of Tamoxifen Adverse Drug Reactions , 2021, Pharmacogenomics and personalized medicine.

[2]  H. E. Meyer zu Schwabedissen,et al.  Nonresponse to high-dose bupropion for depression in a patient carrying CYP2B6*6 and CYP2C19*17 variants: a case report. , 2020, Pharmacogenomics.

[3]  Julia M. Barbarino,et al.  Pharmacogenetic information in Swiss drug labels – a systematic analysis , 2020, The Pharmacogenomics Journal.

[4]  H. Guchelaar,et al.  Phenoconversion of Cytochrome P450 Metabolism: A Systematic Review , 2020, Journal of clinical medicine.

[5]  A. Cross,et al.  Quetiapine and its metabolite norquetiapine: translation from in vitro pharmacology to in vivo efficacy in rodent models , 2016, British journal of pharmacology.

[6]  E. Molden,et al.  Impact of Genetic Variability in CYP2D6, CYP3A5, and ABCB1 on Serum Concentrations of Quetiapine and N-desalkylquetiapine in Psychiatric Patients , 2015, Therapeutic drug monitoring.

[7]  R. Grohmann,et al.  Age and adverse drug reactions from psychopharmacological treatment: data from the AMSP drug surveillance programme in Switzerland. , 2013, Swiss medical weekly.

[8]  E. Molden,et al.  Metabolism of the Active Metabolite of Quetiapine, N-Desalkylquetiapine In Vitro , 2012, Drug Metabolism and Disposition.

[9]  H. Guchelaar,et al.  Pharmacogenetics: From Bench to Byte— An Update of Guidelines , 2011, Clinical pharmacology and therapeutics.

[10]  H. Refsum,et al.  Pharmacokinetic Variability of Quetiapine and the Active Metabolite N-desalkylquetiapine in Psychiatric Patients , 2011, Therapeutic drug monitoring.

[11]  Bryan L Roth,et al.  N-Desalkylquetiapine, a Potent Norepinephrine Reuptake Inhibitor and Partial 5-HT1A Agonist, as a Putative Mediator of Quetiapine's Antidepressant Activity , 2008, Neuropsychopharmacology.

[12]  D. Greenblatt,et al.  Comparison of Duloxetine, Escitalopram, and Sertraline Effects on Cytochrome P450 2D6 Function in Healthy Volunteers , 2007, Journal of clinical psychopharmacology.

[13]  L. Brauer,et al.  Inhibition of CYP2D6 Activity by Bupropion , 2005, Journal of clinical psychopharmacology.

[14]  E. Rüther,et al.  Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP. , 2004, Pharmacopsychiatry.

[15]  E. Rüther,et al.  Severe adverse drug reactions in psychiatric inpatients treated with neuroleptics. , 2004, Pharmacopsychiatry.

[16]  J S Harmatz,et al.  Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[17]  S. Kapur,et al.  A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. , 2000, Archives of general psychiatry.

[18]  S. Grimm,et al.  559 In vitro prediction of potential metabolic drug interactions for seroquel , 1997, Schizophrenia Research.

[19]  S. Hirsch,et al.  Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. , 1997, Archives of general psychiatry.

[20]  M. Hamilton A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.

[21]  H. M. Z. Schwabedissen,et al.  The Role of Pharmacogenomics in Individualized Medicine , 2015 .

[22]  S. Grimm,et al.  Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. , 2006, British journal of clinical pharmacology.

[23]  C. Saller,et al.  Seroquel: biochemical profile of a potential atypical antipsychotic , 2005, Psychopharmacology.

[24]  C. Nemeroff,et al.  Clinical Pharmacokinetics of Quetiapine , 2001, Clinical pharmacokinetics.

[25]  M. Bergström,et al.  Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel®) in patients with schizophrenia , 1998, Psychopharmacology.

[26]  A. Beck,et al.  Assessment of depression: the depression inventory. , 1974, Modern problems of pharmacopsychiatry.